Verapamil plus captopril in moderate-severe hypertensive patients

被引:0
作者
MoraMacia, J
Ocon, J
Garrido, J
Velasco, J
Barcelo, P
机构
来源
NEFROLOGIA | 1996年 / 16卷 / 01期
关键词
verapamil; captopril; moderate-severe hypertension;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objetive: We evaluated with 24 hour ambulatory blood pressure monitoring (ABMP) throughout 24 hours the combination of long acting verapamil once a day plus captopril twice a day (V + C) in moderately-severely hypertensive patients. We also compared choice of dosage between office blood pressure (OBP) and ABMP using this combination therapy. Design and methods: In 21 hypertensive patients who did not respond previously to monotherapy -aged 37-67 y.o., 13 males and 8 females- we meassured OBP and 24-hour-ABPM alter a washout period (PO) and at 4 (PA), 8 (PB) and 12 weeks (PC) with a combination oi V + C. The dossage was: V + C, 240 + 50 mg during PA, ii diastolic OBP was > 89 mmHg it was increased to 360 + 50 mg at PB, and to V + C 360 + 100 mg at PC. Results: OBP al PO in mmHg were: 172 +/- 16/120 +/- 11; at PA 149 +/- 19/102 +/- 9; al PB 144 +/- 24/98 +/- 11, and al PC 142 +/- 23/97 +/- 9, (p < 0.01, ANOVA). Diurnal ABP in mmHg al PO were: 159 +/- 19/107 +/- 11 at PA 141 +/- 23/94 +/- 11, at PB 140 +/- 21/89 +/- 11, and at PC 139 +/- 20/89 +/- 11, (p < 0.01, ANOVA). The number oi patients controlled according to OBP and ABP were at PA: 1/7, at PB: 3/11 and PC: 5/8. Chi square test was significant only when comparing OBP and ABP al PA and PB (p < 0.05). Conclusion: We observed the most important decrease in blood pressure between periods with the initial dosage oi the combination V + C (240 + 50 mg) at PA. However, ABPM showed the best efficacy oi V + C at PB (360 +/- 50 mg). Increasing dosage did not achieved better control oi blood pressure. On the contrary according to the office blood pressure we increased dossage in every period. Thus there is a difference between office blood pressure and diurnal blood pressure monitoring which makes selection of patients and decision of final results different with each method used.
引用
收藏
页码:61 / 67
页数:7
相关论文
共 31 条
  • [1] ALEXANDER RW, 1985, HYPERTENSION, V7, P417
  • [2] ANDERSON A, 1991, J HYPERTENS S6, V9, P380
  • [3] BEVAN EG, 1993, J HUM HYPERTENS, V7, P89
  • [4] BROUWER RML, 1985, J CARDIOVASC PHAR S4, V7, P88
  • [5] ORAL ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR IN LONG-TERM TREATMENT OF HYPERTENSIVE PATIENTS
    BRUNNER, HR
    GAVRAS, H
    WAEBER, B
    KERSHAW, GR
    TURINI, GA
    VUKOVICH, RA
    MCKINSTRY, DN
    GAVRAS, I
    [J]. ANNALS OF INTERNAL MEDICINE, 1979, 90 (01) : 19 - 23
  • [6] CASADEI B, 1991, J HUM HYPERTENS, V5, P31
  • [7] CONWAY J, 1988, J HYPERTENS, V6, P111
  • [8] CRUICKSHANK JM, 1992, J HUM HYPERTENS, V6, P85
  • [9] Fleckenstein A., 1971, CALCIUM HEART, P135
  • [10] FROHLICH ED, 1987, J HYPERTENS, V5, pS43